{"id":"NCT02382276","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol Dependence","officialTitle":"A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol Dependence","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-07-13","primaryCompletion":"2017-01-18","completion":"2017-01-18","firstPosted":"2015-03-06","resultsPosted":"2020-07-20","lastUpdate":"2020-07-20"},"enrollment":405,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Alcohol Dependence"],"interventions":[{"type":"DRUG","name":"Nalmefene hydrochloride","otherNames":[]}],"arms":[{"label":"Nalmefene hydrochloride 20 mg","type":"EXPERIMENTAL"}],"summary":"The long-term safety and efficacy of nalmefene hydrochloride at 20 mg in patients with alcohol dependence will be evaluated in a multicenter, open-label, uncontrolled trial.","primaryOutcome":{"measure":"Number of Participants With Adverse Events","timeFrame":"24-week treatment period","effectByArm":[{"arm":"Nalmefene 20 mg in the lead-in Study","deltaMin":96,"sd":null},{"arm":"Nalmefene 10 mg in the lead-in Study","deltaMin":67,"sd":null},{"arm":"Placebo in the lead-in Study","deltaMin":141,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":7,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":403},"commonTop":["Nausea","Nasopharyngitis","Dizziness","Headache","Malaise"]}}